Point72 Asset Management L.P. Sells 1,206,429 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU)

Point72 Asset Management L.P. cut its stake in Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 54.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,024,989 shares of the company's stock after selling 1,206,429 shares during the quarter. Point72 Asset Management L.P. owned approximately 1.13% of Caribou Biosciences worth $1,630,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of CRBU. JPMorgan Chase & Co. increased its position in Caribou Biosciences by 475.9% during the fourth quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company's stock worth $3,969,000 after buying an additional 2,062,563 shares during the last quarter. Schonfeld Strategic Advisors LLC lifted its stake in shares of Caribou Biosciences by 28.4% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 2,113,272 shares of the company's stock valued at $3,360,000 after buying an additional 467,738 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in shares of Caribou Biosciences in the fourth quarter valued at about $1,921,000. Millennium Management LLC lifted its stake in shares of Caribou Biosciences by 52.9% in the fourth quarter. Millennium Management LLC now owns 859,825 shares of the company's stock valued at $1,367,000 after buying an additional 297,351 shares during the period. Finally, Northern Trust Corp lifted its stake in shares of Caribou Biosciences by 3.4% in the fourth quarter. Northern Trust Corp now owns 714,737 shares of the company's stock valued at $1,136,000 after buying an additional 23,531 shares during the period. 77.51% of the stock is owned by institutional investors and hedge funds.

Caribou Biosciences Trading Up 4.4%

NASDAQ CRBU traded up $0.05 during trading on Tuesday, reaching $1.07. The company's stock had a trading volume of 298,617 shares, compared to its average volume of 1,454,358. The firm has a 50 day moving average price of $0.87 and a 200 day moving average price of $1.35. Caribou Biosciences, Inc. has a 12 month low of $0.66 and a 12 month high of $3.06. The firm has a market capitalization of $99.05 million, a price-to-earnings ratio of -0.65 and a beta of 2.36.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, hitting the consensus estimate of ($0.43). The company had revenue of $2.35 million during the quarter, compared to analysts' expectations of $1.48 million. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. On average, equities analysts forecast that Caribou Biosciences, Inc. will post -1.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating and issued a $3.00 target price (down previously from $9.00) on shares of Caribou Biosciences in a research note on Monday, April 28th. Four analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $7.40.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.